KRAS-4B is the dominant isoform relative to KRAS-4A in human cancers, and it is present in approximately 90% of pancreatic cancers, 30–40% of colon cancers, and 15–20% of lung cancers, mostly NSCLCs5. Here, KRAS is linked to familial pancreatic carcinoma.